



OPEN

Pilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eating

Rajat S. Shivacharan^{1,8}, Camarin E. Rolle^{2,8}, Daniel A. N. Barbosa², Tricia N. Cunningham¹, Austin Feng¹, Noriah D. Johnson^{1,3}, Debra L. Safer³, Cara Bohon³, Corey Keller^{3,4}, Vivek P. Buch¹, Jonathon J. Parker¹, Dan E. Azagury⁵, Peter A. Tass¹, Mahendra T. Bhati^{1,3}, Robert C. Malenka⁶, James D. Lock³ and Casey H. Halpern^{2,7} ✉

Cravings that precede loss of control (LOC) over food consumption present an opportunity for intervention in patients with the binge eating disorder (BED). In this pilot study, we used responsive deep brain stimulation (DBS) to record nucleus accumbens (NAc) electrophysiology during food cravings preceding LOC eating in two patients with BED and severe obesity (trial registration no. NCT03868670). Increased NAc low-frequency oscillations, prominent during food cravings, were used to guide DBS delivery. Over 6 months, we observed improved self-control of food intake and weight loss. These findings provide early support for restoring inhibitory control with electrophysiologically-guided NAc DBS. Further work with increased sample sizes is required to determine the scalability of this approach.

LOC eating, or the subjective sense that one cannot stop eating, is associated with binge eating—defined by the consumption of an objectively large amount of food in a short period of time accompanied by a sense of LOC¹. LOC eating is often characterized by the loss of inhibitory control in response to appetitive cues and cravings leading to binge eating². Recurrent and distressing episodes of binge eating are the key features of BED. BED is the most common eating disorder, affecting up to 3% of US adults, and is the most severe disorder associated with LOC eating based on volume of food consumed¹. It is associated with obesity, decreased quality of life and premature mortality³.

Most treatments for obesity fail to address LOC eating directly, limiting the efficacy of even the most aggressive interventions such as bariatric surgery^{4,5}. Clinical evidence supports a role of cravings for preferred food, or intense desires to consume specific palatable foods, before the onset of LOC and binge eating^{6,7}. Particularly in individuals who are overweight or obese, food cravings have been linked with LOC among those diagnosed with BED⁸. Given this, recent studies have examined neural signals associated with food craving in the pursuit of identifying a biomarker used to trigger DBS (that is, responsive DBS (rDBS)) and inhibit onset of LOC eating when patients may be most at risk.

In the effort to identify such a craving biomarker, previous work in mice found that anticipation of a high-fat food reward was associated with increased low-frequency oscillatory power in the NAc⁹.

This work supported a growing body of evidence across species reporting electrophysiological, neurochemical and functional neuroimaging activities within circuits involving the NAc that correlate with reward anticipation^{10–13} and predict consequential behavioral outcomes¹⁴. Using low-frequency, delta-bandpower as a biomarker to trigger delivery of a brief train of high-frequency electrical stimulation to the NAc (hereafter referred to as rDBS) resulted in substantial and lasting attenuation of binge-like eating in mice sensitized to high-fat food³, whereas conventional, continuous DBS appeared to lose efficacy over time^{15,16}.

In the present study, we report the proof of concept in this human study designed to characterize human NAc electrophysiology of craving as it relates to LOC eating. We sought to identify changes in NAc electrophysiology associated with moments of food craving and LOC eating during controlled in-clinic behavioral tasks and to assess the generalization of this effect to LOC eating events in a naturalistic setting and outside the behavioral laboratory. Finally, we implemented rDBS triggered by NAc electrophysiology identified in behavioral and naturalistic assessments, and report here the initial results on the potential efficacy of this new intervention. The present study was performed under a US Food and Drug Administration (FDA) Investigational Device Exemption (G180079) using the NeuroPace Responsive Neurostimulation (RNS) System¹⁷.

Multi-item buffet: NAc electrophysiology during in-lab LOC eating

We first describe the recording phase. In the assessment of the multi-item buffet, we investigated each subject's LOC by modeling the at-risk environment in a controlled setting¹⁸. Using mood provocation (Supplementary Information), we assessed LOC (1–5 Likert severity scale) during presentation of a high-calorie buffet of the subject's preferred foods while recording synchronized video-NAc local field potential (LFP) activity. Analogous to our pre-clinical work, we analyzed and compared bite onset during the buffet with that in standard meals. Results showed low-frequency power increases immediately before LOC eating. Specifically, increases in left ventral NAc low-frequency (2–8 Hz) power were observed

¹Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA. ²Department of Neurosurgery, Perelman School of Medicine, Richards Medical Research Laboratories, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, PA, USA. ³Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA. ⁴Veterans Affairs Palo Alto Healthcare System and the Sierra-Pacific Mental Illness Research Education, and Clinical Center, Palo Alto, CA, USA. ⁵Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA. ⁶Nancy Pritzker Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA. ⁷Department of Surgery, Corporal Michael J. Crescenz Veterans Affairs Medical Center, PA, USA. ⁸These authors contributed equally: Rajat S. Shivacharan, Camarin E. Rolle. ✉e-mail: casey.halpern@penmedicine.upenn.edu

for both subjects during LOC immediately preceding (within 2 s) the videoed bite-onset (Supplementary Information) power (dB) (mean \pm s.e.m.): subject 1, 2.4 ± 1.5 , $n = 16$ bites; subject 2, 5.6 ± 3.1 , $n = 12$ bites. In contrast, increases in low-frequency power were not observed immediately before bites during standard meals (subject 1, 0.6 ± 1.0 , $n = 15$ bites; subject 2, 0.3 ± 0.9 , $n = 11$ bites) (Fig. 1c, Student's *t*-test, $P < 0.05$). There were no statistical changes in any of the other recorded frequency bands in either subject (Student's *t*-test, $P > 0.05$).

For ambulatory assessment, we analyzed electrophysiology acquired during real-world behavioral states (Supplementary Information) to validate the lab findings. Low-frequency power increases during LOC eating were corroborated with real-world assessments. Specifically, significantly higher low-frequency oscillatory power (Fig. 2a) in the bilateral ventral NAc was found during subject-reported LOC eating events (craving-red trace power (V^2 per Hz) (mean \pm s.e.m.): subject 1, left NAc: 0.21 ± 0.11 , right NAc: 0.16 ± 0.06 , $n = 10$ events; subject 2, left NAc: 0.58 ± 0.14 , right NAc: 0.21 ± 0.07 , $n = 71$ events) when compared with control periods (control-black trace, subject 1, left NAc: 0.1 ± 0.04 , right NAc: 0.04 ± 0.01 , $n = 9$ events; subject 2, left NAc: 0.19 ± 0.04 , right NAc: 0.09 ± 0.04 , $n = 80$ events) and periods of hunger (hunger-blue trace, subject 1, left NAc: 0.06 ± 0.01 , right NAc: 0.03 ± 0.01 , $n = 13$ events; subject 2, left NAc: 0.27 ± 0.11 , right NAc: 0.11 ± 0.03 , $n = 37$ events) (Fig. 2a, one-way ANOVA, subject 1, left NAc: $F = 3.50$, $P = 0.04$, right NAc: $F = 4.95$, $P = 0.03$; subject 2, left NAc: $F = 5.14$, $P = 0.02$, right NAc: $F = 0.07$, $P = 0.93$). Consistent with the in-clinic tasks, there were no differences in any other frequency band during at-risk moments in the ambulatory setting.

For each subject, we programmed the device to detect brief increases in low-frequency activity in both the left and the right ventral NAc. To confirm that the signal being detected was in the low-frequency range, we analyzed the power spectra of the NAc LFP activity in the 5 s before detection and found that the area detectors (Supplementary Information) were detecting low-frequency activity in the left and right ventral NAc (Fig. 2b). For this analysis, we compared detection made in stored LFPs during reported LOC eating events and awake events. For subject 1, increased low-frequency power compared with baseline NAc LFP signal (average 2-min window) was identified in 74.4% (67/90) of reported LOC eating event detections and 63.2% (84/133) of the awake detections ($\chi^2(1, n = 223) = 24.54$, $P < 0.05$). For subject 2, increased low-frequency power was identified in 76.9% (30/39) reported LOC eating event detections and 45.8% (22/48) awake detections ($\chi^2(1, n = 87) = 14.82$, $P < 0.05$).

Considering the stimulation phase, both subjects reported an increased sense of self-regulation and control over food intake specific to cravings and related eating behavior. Furthermore, both subjects showed a decrease in the reported frequency of LOC eating events from baseline to 6 months post-stimulation (that is, the primary endpoint), as assessed by the Eating Disorder Examination (EDE), and LOC severity, as assessed by the Eating Loss of Control Scale (ELOCS), across the 28-d period during the baseline month compared with 6 months after the stimulation month (LOC

frequency: subject 1 = 80% decrease; subject 2 = 87% decrease; LOC episode severity: subject 1: 9-point improvement ($P = 0.09$); subject 2: 15-point improvement ($P = 0.05$)) (Extended Data Fig. 1a,b). Notably, by the end of the 6-month follow-up period, subject 1 exhibited substantial improvement in BED severity, whereas subject 2 no longer met criteria for BED (that is, fewer than average of four binge eating events per month over the prior consecutive 3 months for no more BED diagnosis), which met our primary endpoint (Extended Data Fig. 1c). Corroborating their subjective reports (Extended Data Fig. 1), 6-month outcomes showed a decrease in body weight (kg and percentage reduction) and body mass index (BMI) for both subjects: subject 1 = -5.9 kg, -4.5% and -2.2 kg m $^{-2}$, respectively; subject 2 = -8.2 kg, -5.8% and -2.9 kg m $^{-2}$, respectively (Extended Data Fig. 1d,e). Month-to-month reports of Ecological Momentary Assessment (EMA), ELOCS ratings and weight (kg)/BMI are reported for both subjects in Supplementary Figs. 3.1–3.6.


Discussion

The present study identified NAc low-frequency oscillatory power as a signal associated with LOC craving, and then implemented this biomarker to guide rDBS delivery in two subjects with BED and severe obesity. In the recording phase, in-lab assessments implicated NAc low-frequency signaling during naturalistic LOC eating. The generalizability of this signal to real-world settings was then corroborated by our finding that low-frequency oscillatory power was increased during real-world LOC eating events compared with non-LOC events. In the stimulation phase, 6 months of bilateral NAc rDBS triggered by low-frequency power was found to improve LOC eating, as well as reduce body weight and BMI. Optimization of stimulation parameters is still ongoing in both subjects, and four additional subjects are expected to be implanted after a supplement approval to our investigational device exemption. The present study was a safety and feasibility assessment and LOC was the primary endpoint. As such, we did not control for changes in lifestyle or diet. However, we used single-blind subjects during stimulation to rule out stimulation-induced side effects and placebo effects. Moreover, subjects 1 and 2 both reported making healthier choices around food and having interest in being more physically active, although neither patient enrolled in any regular exercise or diet program during this 6-month follow-up. Therefore, we have found that, by ameliorating LOC through NAc stimulation, we've helped patients with severe obesity lose weight without providing them instruction or guidance on a dietary plan. This supports the stimulation-induced restoration of control in these subjects being the underlying mechanism of BMI improvement.


We encountered early challenges when capturing LOC eating events in the real world. A training period was necessary before surgery for both subjects to learn to identify and document their LOC eating behaviors. This involved having a psychiatrist (D.S.) with expertise in obesity and eating disorders discuss with each patient her personal understanding of LOC eating. As we report (Supplementary Information), although sensitivity of low-frequency detections to LOC eating was high, low-frequency oscillations in the NAc were not always specific to food craving and LOC eating

Fig. 1 | Initial characterization of human accumbens electrophysiological signal provoked by exposure to preferred food stimuli. **a**, Schematic of the multi-stage, staggered enrollment, early feasibility study design (NCT03868670). The current stage of each participant within the trial is highlighted (blue, subject 1; green, subject 2). **b**, Two quadripolar depth electrodes placed bilaterally in the NAc. Stereotactic coordinate with fGATIR and T1 images were used for direct targeting optimization of the electrode trajectory within the NAc. NAc-Red, anterior limb of internal capsule, orange; putamen, yellow; caudate, blue. Coordinates are detailed in Supplementary Table 2. **c**, The multi-item buffet of preferred foods allowing us to examine NAc electrophysiology during LOC eating as well as the preceding in-lab standardized meals. The 2 s preceding a bite was quantified during LOC versus standard meals. Both participants reported LOC after mood provocation, which correlated with significant low-frequency increases in power (2–8 Hz) during the 2 s preceding a bite when compared with standard meal bites (buffet (red): subject 1, 2.4 ± 1.5 dB, $n = 16$ bites; subject 2, 5.6 ± 3.1 dB, $n = 12$ bites; standard meal (black): subject 1, 0.6 ± 1.0 dB, $n = 15$ bites; subject 2, 0.3 ± 0.9 dB, $n = 11$ bites; Student's *t*-test, $P < 0.05$). BP, bandpower. Bar graphs with error bars are presented as mean bandpower \pm s.e.m.


a




b



c





compared with non-LOC eating events. Ongoing work seeks to optimize detection algorithms and improve the sensitivity and specificity of rDBS for LOC eating. Furthermore, real-world LOC electrophysiology detected from ambulatory recordings was specific

to bilateral, ventral Nac delta (2–4 Hz), whereas in-lab experiments found effects in both delta and theta (2–8 Hz) and were limited to the left ventral Nac. We believe this inconsistency to be grounded in the methodological variance between the in-lab buffet task procedures

Fig. 2 | Bilateral NAc low-frequency oscillation captured during self-reported, at-risk moments for LOC eating. **a**, Both subjects reporting LOC eating events (high craving, low hunger) in the real world consistent with the diagnosis of BED, and kept a food diary describing the LOC, craving and hunger intensity. Analysis of the left and right ventral NAc showed an increase in low-frequency oscillations during LOC eating when subjects experienced craving, compared with hunger and control periods (blue arrow corresponds to frequency quantified in bandpower insert). This increase in low frequency was observed in both our subjects (craving-red trace: power (V^2 (volts squared) per Hz) (mean \pm s.e.m.): subject 1, left NAc: 0.21 ± 0.11 , right NAc: 0.16 ± 0.06 , $n = 10$ events; subject 2, left NAc: 0.58 ± 0.14 , right NAc: 0.21 ± 0.07 , $n = 71$ events; control-black trace: subject 1, left NAc: 0.1 ± 0.04 , right NAc: 0.04 ± 0.01 , $n = 9$ events; subject 2, left NAc: 0.19 ± 0.04 , right NAc: 0.09 ± 0.04 , $n = 80$ events; hunger-blue trace: subject 1, left NAc: 0.06 ± 0.01 ; right NAc: 0.03 ± 0.01 , $n = 13$ events; subject 2, left NAc: 0.27 ± 0.11 , right NAc: 0.11 ± 0.03 , $n = 37$ events; corrected for multiple comparisons with P value adjustment for the three conditions using Bonferroni's corrections (ANOVA, followed by Student's t -tests comparing each state): subject 1, left NAc: $F = 3.50$, $P = 0.04$; right NAc: $F = 4.95$, $P = 0.03$; subject 2, left NAc: $F = 5.14$, $P = 0.02$, right NAc: $F = 0.07$, $P = 0.93$, $^{**}P < 0.05$). **b**, The detection algorithms programmed to detect low frequency in both left and right ventral NAc simultaneously. An analysis of the LFP time-locked to low frequency triggered detections captured over 8 weeks during scheduled awake and user-initiated LOC recordings and confirmed that our detection algorithms were indeed detecting changes in low-frequency power. Bar graphs with error bars are presented as mean bandpower \pm s.e.m.

and the ambulatory data acquisition procedures. The NAc signal acquired during the in-lab buffet task NAc was time-locked to bites during an LOC eating episode (2 s preceding a bite), whereas the ambulatory data were time-locked to moments of craving preceding an LOC eating episode (60 s preceding a user-initiated magnet swipe). Although cravings are a relevant and important precedent to LOC eating, they capture a signal that is characteristically different from the signal during eating itself. Furthermore, there is a substantial difference in the duration captured (and averaged over) between the two types of data acquisition, which could certainly contribute to the variance in results. Secondly, the in-lab buffet task captures an LOC eating episode that is clinically provoked using emotional content, whereas the ambulatory data are acquired during all LOC eating episodes. Real-world LOC can be provoked for a number of reasons and by a combination of factors not entirely captured by mood provocation in the lab. Therefore, it is possible that the specificity of in-lab procedures during the buffet task did not capture all dimensions of LOC eating that the ambulatory data did. We also note that, although the frequencies within which we found our effects contained the delta signal identified in mice⁹, the effects from in-lab testing were broader and inclusive of theta frequencies. It's important to mention that it is difficult to disambiguate the clinical value of the presence of low-frequency peaks, compared with the frequency of low-frequency peaks, in predicting LOC eating events. We believe that this is an interesting scientific query that would be better answered by more targeted analyses of low-frequency power and LOC eating. Importantly, one difficulty with the low-frequency biomarker signal is its presence during normal physiological processes such as sleep^{19,20}. To account for detection and stimulation during sleep, we limited rDBS delivery to awake hours (7am–10pm). Finally, the upfront cost of implantable devices is high; thus long-term follow-up of LOC eating as well as BMI beyond the study period will be necessary to assess societal cost-effectiveness of this intervention based on our decision analyses²¹.

In conclusion, NAc rDBS improved LOC eating frequency and severity in two patients with BED and severe obesity. These findings were associated with weight loss even during this early follow-up period, suggesting that patients can lose weight without instruction to change their diet or physical activity (efforts that are often unsuccessful). This is a testament to the potential clinical impact of this new intervention and supports continued study in this FDA-guided, human, early feasibility trial.

Online content

Any methods, additional references, Nature Research reporting summaries, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-022-01941-w>.

Received: 8 March 2022; Accepted: 8 July 2022;

Published online: 29 August 2022

References

- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 5th edn (American Psychiatric Association, 2013).
- Reents, J. & Pedersen, A. Differences in food craving in individuals with obesity with and without binge eating disorder. *Front Psychol.* **12**, 660880 (2021).
- Hudson, J. I. et al. Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder. *Am. J. Clin. Nutr.* **91**, 1568–1573 (2010).
- White, M. A., Kalarichian, M. A., Masheb, R. M., Marcus, M. D. & Grilo, C. M. Loss of control over eating predicts outcomes in bariatric surgery patients: a prospective, 24-month follow-up study. *J. Clin. Psychiatry* **71**, 175–184 (2010).
- Chao, A. M. et al. Binge-eating disorder and the outcome of bariatric surgery in a prospective, observational study: two-year results. *Obesity* **24**, 2327–2333 (2016).
- Gruzca, R. A., Przybeck, T. R. & Cloninger, C. R. Prevalence and correlates of binge eating disorder in a community sample. *Compr. Psychiatry* **48**, 124–131 (2007).
- McCuen-Wurst, C., Ruggieri, M. & Allison, K. C. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. *Ann. N.Y. Acad. Sci.* **1411**, 96–105 (2018).
- Bohon, C., Stice, E. & Spoor, S. Female emotional eaters show abnormalities in consummatory and anticipatory food reward: a functional magnetic resonance imaging study. *Int. J. Eat. Disord.* **42**, 210–221 (2009).
- Wu, H. et al. Closing the loop on impulsivity via nucleus accumbens delta-band activity in mice and man. *Proc. Natl Acad. Sci. USA* **115**, 192–197 (2018).
- Roitman, M. E., Stuber, G. D., Phillips, P. E., Wightman, R. M. & Carelli, R. M. Dopamine operates as a subsecond modulator of food seeking. *J. Neurosci.* **24**, 1265–1271 (2004).
- Smith, C. T. et al. Modulation of impulsivity and reward sensitivity in intertemporal choice by striatal and midbrain dopamine synthesis in healthy adults. *J. Neurophysiol.* **115**, 1146–1156 (2016).
- Taha, S. A. & Fields, H. L. Inhibitions of nucleus accumbens neurons encode a gating signal for reward-directed behavior. *J. Neurosci.* **26**, 217–222 (2006).
- Christoffel, D. J. et al. Input-specific modulation of murine nucleus accumbens differentially regulates hedonic feeding. *Nat. Commun.* **12**, 2135 (2021).
- Demos, K. E., Heatherton, T. F. & Kelley, W. M. Individual differences in nucleus accumbens activity to food and sexual images predict weight gain and sexual behavior. *J. Neurosci.* **32**, 5549–5552 (2012).
- Wu, H. et al. Local accumbens in vivo imaging during deep brain stimulation reveals a strategy-dependent amelioration of hedonic feeding. *Proc. Natl Acad. Sci. USA* **119**, e2109269118 (2022).
- Halpern, C. H. et al. Amelioration of binge eating by nucleus accumbens shell deep brain stimulation in mice involves D2 receptor modulation. *J. Neurosci.* **33**, 7122–7129 (2013).
- Wu, H. et al. Brain-responsive neurostimulation for loss of control eating: early feasibility study. *Neurosurgery* **87**, 1277–1288 (2020).
- Telch, C. F. & Agras, W. S. Do emotional states influence binge eating in the obese? *Int. J. Eat. Disord.* **20**, 271–279 (1996).
- Adamantidis, A. R., Gutierrez Herrera, C. & Gent, T. C. Oscillating circuitries in the sleeping brain. *Nat. Rev. Neurosci.* **20**, 746–762 (2019).
- Oishi, Y. et al. Slow-wave sleep is controlled by a subset of nucleus accumbens core neurons in mice. *Nat. Commun.* **8**, 734 (2017).

21. Mahajan, U. V. et al. Can responsive deep brain stimulation be a cost-effective treatment for severe obesity? *Clin. Trials Investig.* **0**, 1–9 (2021).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to

the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022

Methods

This research complies with and was approved by Stanford's Institutional Review Board (IRB-46563). The study protocol for this clinical trial (trial registration no. NCT03868670) is publicly available as a supplement to this manuscript. Data presented in this manuscript can be requested within reason by contacting the corresponding author (see Data availability for additional details). As previously described, the clinical trial is a multi-stage early feasibility study with staggered enrollment (Fig. 1a, see protocol paper for more details¹⁷). All participant information, magnetic resonance imaging (MRI), computed tomography (CT), LFP and behavior data were collected under a Stanford University IRB-approved protocol (IRB no. 46563, NCT03868670).

Prestudy procedures. *Subjects.* Two adult women with BED and treatment-refractory, severe (grade III) obesity, despite bariatric surgery, were recruited for the present study. The first participant (subject 1), a 45-year-old white woman with a BMI of 46 kg m⁻², underwent roux-en-Y gastric bypass (RYGB) in 2005 and experienced an initial weight loss of 52.16 kg. However, the participant gradually regained the weight. At the time of enrollment, she was back to her pre-RYGB weight and met DSM-V criteria¹ for BED, reporting at least five LOC eating bouts per week, with three LOC eating events per week as well. At the time of enrollment, she had co-morbidities of neoplasm, lower back pain, kyphoscoliosis/scoliosis, hypertension, esophageal reflux, dyslipidemia, complicated migraine and anxiety. The second participant (subject 2), a 56-year-old white woman with a BMI of 47 kg m⁻², underwent RYGB in 2005 and initially lost 68.95 kg. Subject 2 maintained this weight loss for 6 years; however, she regained the weight in 2009 while both caring for an ill family member and recovering from a car accident. At the time of study enrollment, she was within 9% of her pre-RYGB weight and she reported LOC eating four times a week and met criteria for BED as well. At the time of enrollment, she had a migraine co-morbidity. Both subjects reported severe cravings related to emotional and/or stress-related triggers that led to LOC eating. In addition to the RYGB, both subjects tried numerous other weight-loss strategies including exercise, dieting, support groups and medication, as was required by our enrollment criteria.

The study was approved by Stanford's IRB (IRB-46563) (see Supplementary Information for participant characteristics) and informed consent was obtained from all subjects. Neither participant was compensated for their participation.

Study design. Designed with a staggered enrollment, each subject progressed through the study stages shown in Fig. 1a. Both subjects underwent stereotactic implantation of bilateral depth electrodes, each with four contacts. The two distal contacts of the DBS leads were positioned in the NAc, verified by both indirect and direct targeting strategies noted earlier, with the two more proximal contacts traversing the anterior limb of the internal capsule (Fig. 1b and Supplementary Table 2)²². The preoperative MRI anatomical images were co-registered to a post-surgical CT scan using advanced normalization tools (ANTs²³) for electrode localization²⁴. The electrode artifacts from the co-registered postoperative CT, together with the preoperative MRI and atlas-based regions of interest, were then loaded in DSI Studio for three-dimensional rendering (<https://dsi-studio.labsolver.org>), as presented in Fig. 1b.

Implantation → Recording phase (6 months) → Stimulation phase (12 months; see Fig. 1a).

Responsive DBS system. The closed-loop intracranial stimulation system used here for rDBS was a brain RNS System (NeuroPace, Inc.) currently approved by the US FDA for the treatment of adults with medically refractory focal-onset seizures. The system consists of two intracranial recording and stimulating electrodes connected to a neurostimulator implanted in the skull. The neurostimulator continuously monitors electrographic signals and detects abnormal electrophysiological activity to trigger brief bursts of electrical stimulation. The RNS System stores hourly counts of detected events as well as multiple 1- to 3-min snapshots of LFP activity, which are uploaded to a computer and server where they can be analyzed and reviewed. This system allows the opportunity to collect and examine electrographic activity of the NAc in a subject's naturalistic environment during vulnerable periods of craving that precede LOC eating events.

Stereotactic targeting, device implantation and recording configuration. After screening by a multidisciplinary team, the subjects underwent surgical placement of the cranial neurostimulator attached to two depth leads (four contacts each, 3.5-mm electrode spacing) (NeuroPace, Inc.) targeting the NAc bilaterally (Fig. 1b). Direct targeting of the NAc using Fast Gray Matter Acquisition T1 Inversion Recovery (fGMAT1) MRI was implemented. Due to the investigative nature of the present study, the neurostimulator (250-Hz sampling rate) was programmed with the high-pass filter set to 1 Hz and the low-pass filter set to 90 Hz, the widest range available on the device. From each hemisphere, the neurostimulator stores two channels of differential recordings each made up of one NAc electrode pair (contacts 1 and 2) and another electrode pair in the white matter of the anterior limb of the internal capsule (contacts 3 and 4) to make up a ventral NAc (contacts 1 and 3) and dorsal NAc (contacts 2 and 4) recording. Implantation was performed for subject 1 on 31 January 2020 and for subject 2 on 17 July 2020.

Recording phase. Immediately after implantation, the subjects entered a 6-month recording phase, during which naturalistic in-lab assessments and ambulatory real-world assessments were performed to identify an electrophysiological biomarker for rDBS in the consecutive stimulation phase. From each hemisphere, activity was recorded from the ventral and dorsal NAc (see Supplementary Information for details).

During the end of the recording phase of the study and after optimization of signal detection, both subjects underwent a day of monopolar survey testing of all the electrode contacts to screen for any acute stimulation effects. One week after this survey testing, each subject was randomized in a single-blind fashion to receive a week of active or sham rDBS unilaterally to assess initial tolerability and optimize stimulation parameters. One subject was randomized to active stimulation and the other sham stimulation. For subject 1, stimulation was administered at 3 mA unilateral for a week, off for a week, 5 mA unilateral for 4 weeks. The subject was unblinded after these 4 weeks and transitioned to open-label stimulation. For subject 2, stimulation was administered at 0.5 mA unilateral for a week, off for a week, 1 mA bilateral (split between two leads) for 4 weeks. The subject randomized to sham stimulation underwent a week of active stimulation testing before transitioning into the open-label phase. Stimulation was well tolerated throughout this protocol with no adverse effects.

Behavioral Assessments. Subjects underwent two assessments to evaluate NAc electrophysiology during: (1) anticipation (pre-consumption) of food during standard meals and LOC eating (that is, multi-item buffet assessment, in-lab naturalistic testing); and (2) states of hunger and craving (pre-consumption) (that is, ambulatory assessment, real-world testing). All behavioral assessments were collected during the recording phase (see Fig. 1a).

Multi-item buffet. Subjects participated in a modified multi-item buffet designed to provoke LOC eating in a more naturalistic setting (developed by W. Stuart Agras¹⁸). This buffet of preferred foods was intended to model the at-risk environment of LOC in a controlled setting where real-time brain recordings could be synchronized to video monitoring. For this task, subjects spent the day in this behavioral lab where they were served a breakfast and lunch (~1,000 kcal total). After a mood provocation protocol with an eating disorder psychiatrist (D.S.), the subjects were presented with a 5,000-kcal calorie buffet of preferred foods. The mood provocation was administered based on research showing that negative affective states, compared with neutral mood provocations, are more likely to trigger loss of control/disinhibited eating in patients who binge eat¹⁸. During the buffet, real-time video with eye tracking (Pupil Lab Pupil Core Eyetracker (<https://pupil-labs.com/products/core>) and room video) and NAc LFP activity were recorded to capture bites (see Fig. 1c, picture insert²⁵). Subjects reported their level of LOC before, during and after the presentation of the foods. The buffet was stopped 15 min after the subject would verbalize that they were experiencing LOC per FDA safety guidelines.

Ambulatory assessment. Due to storage capacity limitations, the neurostimulator does not store continuous LFP activity; however, it does record multiple LFP snapshots of activity when an event is detected, based on time of day or when the subject triggers storage (by swiping a magnet over the device). To assess LOC in the real world, subjects were instructed to trigger LFP activity storage (180 s for subject 1, 90 s for subject 2) whenever they had a craving and were about to eat. The storage time was different for each subject based on understanding the subject's LOC behavior (for example, subject 2's LOC revolved around multiple snacking events so they would report LOC more frequently) and how many events we could store without losing data. The subjects noted the day and time of the events in a diary and also provided Likert ratings of LOC severity, craving and hunger during these times. In addition to swiping the magnet for cravings, subjects were asked to swipe the magnet when they felt relaxed/normal to timestamp control periods. Detections were also scheduled to be stored during a randomly selected time of the day during awake (awake detections) and sleep (sleep detections) hours. Both of these events are scheduled LFP recordings that are not user initiated and not tied to an LOC event. As such, low-frequency detections acquired during these scheduled events act as controls to LOC detections and user-initiated events. Our primary analyses were designed to compare NAc LFP activity recorded during reported LOC versus control period magnet swipes. For both subjects, LOC was identified early on to be frequently associated with events of craving in the absence of hunger. In fact, both subjects noted qualitative differences in craving severity with higher severity cravings (referred to as high craving) being associated with LOC-related binges historically. Thus, for our study purposes, the presence of high craving with no hunger (that is, subjects felt at risk of losing control even though they were not hungry) was defined as an at-risk moment, and is referred to as a 'LOC eating event'. In contrast, events of hunger sensations even in the context of craving (potentially closer to 'typical eating' behavior in the presence of metabolic need) were not associated with reported LOC. Subject reporting of LOC using the magnet swipe feature is probably one of the first of its kind, and a very new method for assessing ambulatory, real-world conditions.

Stimulation phase. After the recording phase, both subjects underwent single-blinded stimulation survey testing in which they received brief bursts of

electrical stimulation across all electrode contacts to screen for acute effects. This was followed by a single-blinded, staged, on-off stimulation safety testing period to assess for possible side effects of rDBS. Subjects then entered the 10- to 12-month open-label stimulation phase of the study. In this phase, rDBS was delivered using a bipolar montage of the two ventral contacts on the lead (contacts 1 and 2) on each left and right electrode positioned within the NAc (Fig. 1b). Both subjects received bilateral NAc rDBS via depth electrodes connected to a NeuroPace RNS System to detect and inhibit LOC eating events. Stimulation was delivered at 125 Hz in two 5-s bursts at a charge density of $0.5 \mu\text{C cm}^{-2}$. Current was incrementally increased over 6 months in both subjects, resulting in a stimulation charge density of $1.5 \mu\text{C cm}^{-2}$. Detections and stimulations occurred approximately 400 times a day with a stimulation limit set to 700 bouts (or approximately 117 min) per day to limit unnecessary stimulation at night (Supplementary Figs. 4.1 and 4.2). The recording phase was used to identify the biomarker that the rDBS would respond to, whereas the stimulation phase was used to test the safety and side effects of stimulation. Stimulation parameters were derived from those used in epilepsy and thought to have a disruptive effect on the target neural activation^{26–28}. Stimulation was started at a low amplitude using contacts that a monopolar assessment previously revealed to elevate mood to avoid well-described, DBS-induced side effects to this region such as hypomania. Stimulation was started unilaterally per FDA guidance and added stimulation to the contralateral hemisphere, and then slowly titrated every 3 months until an improvement in LOC was detected. Frequency and pulse width were held constant such that only changes in amperage were made.

Based on the recording phase, each subject's device was programmed to detect brief increases in low-frequency activity in both the left and the right ventral NAc (Supplementary Information). These detections of low-frequency activity triggered bilateral NAc rDBS ($\sim 1 \mu\text{C cm}^{-2}$ charge density, 10-s duration). Low-frequency triggered bilateral stimulation has been well tolerated by both subjects. Neither subject 1 nor subject 2 experienced a serious adverse event and all reported events were self-limited (Supplementary Table 1). Examination of sensitivity and specificity can be found in Supplementary Figs. 1 and 2.

High-frequency DBS has been widely used to effectively treat symptoms in psychiatry (for review see Sullivan et al.²⁹). High-frequency stimulation has been found to both excite and suppress neural activation in different ways, and therefore it has been difficult to pinpoint the direct mechanism of action. However, although there are a number of theories surrounding the mechanism of action of high-frequency DBS, only one common mechanism has been found to explain the various neural effects found from high-frequency stimulation: DBS dissociates input and output signals in the stimulated nucleus and disrupts abnormal information flow in pathological conditions (aligning with the 'disruption hypothesis' of stimulation)³⁰. Furthermore, therapeutic effect has been linked to effective suppression of low-frequency oscillations, which was accomplished only by high-frequency stimulation^{17,30}.

Data collection and analyses. *LFP analyses.* All LFP data analyses were performed in R2014b (Mathworks Inc.) using customized scripts built on the FieldTrip Toolbox³¹ (Donders Institute for Brain, Cognition and Behaviour, Radboud University, the Netherlands; see <http://fieldtriptoolbox.org>).

Electrophysiological data were recorded at 250 Hz and bipolar re-referenced online. The recorded LFP data were cleaned offline, using the following steps: (1) de-trending raw LFP data; (2) 60-Hz (and harmonics: 120-Hz, 180-Hz) notch filters; and (3) 1- to 90-Hz bandpass filter. The cleaned data were then epoched with respect to the trial onset or, in the case of ambulatory data, centered at the time of the magnet swipe. LFP data recorded during stimulation trials were not analyzed due to the high-frequency nature of the stimulation and associated artifact in the recording.

All spectral analyses were computed at each channel. Data underwent morlet wavelet time frequency transformation and then the power was averaged within the canonical frequencies: delta (2–4 Hz), theta (4–8 Hz), alpha (8–12 Hz), beta (13–30 Hz), gamma (31–50 Hz) and high-gamma (50–90 Hz) frequency bands. In some cases, we analyzed low-frequency power combining delta–theta (2–8 Hz). Average estimates of bandpower were derived by taking the mean power across the frequencies within each predefined canonical frequency band with the s.e.m. reported. Ambulatory: data epoch was extracted in the pre-magnet swipe time (1–2 min) before undergoing above spectral analysis. Multi-item buffet: data epochs were extracted 2 s before the time-locked bite within each task condition—standard eating and LOC eating. Bites were defined as the moment food entered the subject's mouth, as defined by visual inspection of synchronized eye tracking (Pupil Lab Pupil Core Eye-tracker (<https://pupil-labs.com/products/core>)) and video captured during the task. The 2-s windows were chosen based on our previous pre-clinical mouse work looking at the same window with mice approaching the high-fat food³ and examining time-locked eye tracking and video per bite examining time lingering on food in hand/spoon or food coming to mouth. LFP data were captured using the neurostimulator's magnet feature for storing which was wireless controlled by the research team in an adjacent room with a field of view on the subject behind a one-way mirror window.

Statistical analyses. Statistical analysis (Minitab Data and Statistical Toolbox) was performed using two-sided Student's *t*-test to compare bandpower means during clinical tasks. One-way analysis of variance (ANOVA) followed by Student's *t*-test

was performed comparing mean power during ambulatory recordings under three conditions (control, craving, hunger). The χ^2 test was performed on the rDBS detection count for each subject. A statistical significance criterion of $\alpha = 0.05$ was used for all tests. Results are shown as a mean \pm s.e.m. unless otherwise noted.

Signal detection. For each subject, we programmed the device to detect brief increases in low-frequency activity in both the left and right ventral NAc. To help differentiate the brief bursts of low-frequency activity associated with LOC from the longer periods of delta activity observed during sleep, we selected the RNS System 'Area' detector. The area under the curve (AUC) detector takes a signal AUC measurement every 2 s (short-term trend) and compares it with an average of AUC measurements from the past 2 min (long-term trend). If the current (short-term) AUC measurement exceeds the average long-term trend measurements of AUC, by the programmed threshold (in our cases by 63–100%), a detection is made. Stimulation detection threshold was determined by the analyses of the abnormal NAc activity. As the low-frequency activity observed during sleep increases the longer-term AUC, it is difficult for the short-term AUC measurement to exceed the longer-term AUC value by the specified threshold, thereby reducing the amount of activity detected during sleep. As we observed increases in low-frequency power during real-world LOC in both the left and the right ventral NAc, we also required the activity to be present simultaneously in both the left and the right NAc for the detection to trigger rDBS delivery.

Clinical measures. The primary study endpoint is at least 50% of subjects exhibiting a decrease in the number of LOC eating events per week, utilizing the Ecological Momentary Assessment (EMA). Reported below are preliminary EMA data from subjects 1 and 2, as well as additional support from the monthly surveys and ELOCS:

- (1) EMA: 1 week out of every month, participants receive a survey at two semi-random times per day (morning and evening) that asks about eating behaviors, including frequency and severity of loss of control. Supplementary Figs. 3.1 and 3.3 display the number of LOC eating events per 28 d, which is the endpoint for the study (any reduction in LOC from baseline), for subjects 1 and 2, respectively.
- (2) ELOCS: a retrospective survey assessed once a month targeting LOC frequency and severity. Supplementary Figs. 3.2 and 3.4 for subjects 1 and 2 display the LOC frequency score and LOC frequency severity based on this 18-item assessment.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The data that support the findings of the present study are available upon reasonable request to the corresponding author (C.H.H.). The data are not publicly available yet, due to them containing information that could compromise research participant privacy/consent. As this is part of an ongoing clinical trial, enrolling additional subjects (trial registration no. NCT03868670), all data will be deposited into the Data Archive Brain Initiative (<https://dabi.loni.usc.edu>) as part of the BRAIN Initiative on completion of the study. During this time, any request will be reviewed in a timely manner by the corresponding author, corresponding author's institution and ultimately shared within reason of a signed data transfer agreement.

Code availability

All code has been made publicly available and can be found at https://github.com/rajatss123/LOC_NM_Code.

References

22. Barbosa, D. A., Kuijper, F. M., Duda, J., Wang, A. R., Cartmell, S. C., Saluja, S., ... & Halpern, C. H. (2022). Aberrant impulse control circuitry in obesity. *Molecular psychiatry*, 1–11. Chicago
23. Avants, B. B., Tustison, N., & Song, G. Advanced normalization tools (ANTS). *Insight J*, 2, 1–35 (2009).
24. Kakusa, B. et al. Anticipatory human subthalamic area beta-band power responses to dissociable tastes correlate with weight gain. *Neurobiol. Dis.* **154**, 105348 (2021).
25. Topalovic, U. et al. Wireless programmable recording and stimulation of deep brain activity in freely moving humans. *Neuron* **108**, 322–334 e329 (2020).
26. Chiken, S. & Nambu, A. Mechanism of deep brain stimulation: inhibition, excitation, or disruption? *Neuroscientist* **22**, 313–322 (2016).
27. Ramasubbu, R., Lang, S. & Kiss, Z. H. T. Dosing of electrical parameters in deep brain stimulation (DBS) for intractable depression: a review of clinical studies. *Front. Psychiatry* **9**, 302 (2018).
28. Thomas, G. P. & Jobst, B. C. Critical review of the responsive neurostimulator system for epilepsy. *Med. Devices* **8**, 405–411 (2015).
29. Sullivan, C. R. P., Olsen, S. & Widge, A. S. Deep brain stimulation for psychiatric disorders: from focal brain targets to cognitive networks. *Neuroimage* **225**, 117515 (2021).

30. McConnell, G. C., So, R. Q., Hilliard, J. D., Lopomo, P. & Grill, W. M. Effective deep brain stimulation suppresses low-frequency network oscillations in the basal ganglia by regularizing neural firing patterns. *J. Neurosci.* **32**, 15657–15668 (2012).
31. Oostenveld, R., Fries, P., Maris, E. & Schoffelen, J. M. FieldTrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data. *Comput. Intell. Neurosci.* **2011**, 156869 (2011).

Acknowledgements

This work was supported by the National Institutes of Health (grant no. 5UH3NS103446-02 and 1R01MH124760-01A1 CHH). C.H.H. received funding for this work from the Blume Foundation. C.J.K. was supported by grant no. R01MH129018 and the Burroughs Wellcome Fund Career Award for Medical Scientists. P.A.T. gratefully acknowledges funding support by the John A. Blume Foundation. C.B. was supported by the National Institute of Mental Health (grant no. K23 MH106794). We thank the study subjects for their dedication and commitment to this new, human exploratory trial, and the members of the Stanford Clinical and Translational Research Unit and the Departments of Neurosurgery and Psychiatry at Stanford Medicine for space to conduct in-clinic assessments, the Suthana laboratory for in-clinic tool support, I. Kratter, T. Prieto, V. Ngo and B. Sanjanwala for support during surgery and intraoperative testing and E. Mirro, T. L. Skarpaas, N. Hasulak and T. Tchong for providing technical support for the NeuroPace RNS System.

Author contributions

R.S.S., C.E.R. and C.H.H. wrote the manuscript with valuable input from all authors. R.S.S., C.E.R., D.A.N.B., T.N.C., V.P.B., A.F., D.L.S., J.J.P., M.T.B. and N.J. conducted clinical and electrophysiological data collection. R.S.S. and C.E.R. conducted data

analyses. T.C., D.S., M.T.B. and C.H.H. performed behavior analyses. C.H.H., V.P.B. and J.J.P. performed surgical procedures. C.H.H., C.B., C.J.K., V.P.B., J.J.P., D.E.A., P.A.T., M.T.B., R.C.M. and J.D.L. provided supervision and guidance throughout the study. C.H.H. provided financial support to conduct the present study.

Competing interests

No funding from NeuroPace was received for the present study nor were data analyses reported here conducted by NeuroPace employees. C.H.H., R.S.S. and C.E.R. have patents related to sensing and brain stimulation for the treatment of neuropsychiatric disorders. V.P.B. is a consultant for NeuroPace Inc. and receives honoraria for educational lectures. C.J.K. holds equity in Alto Neuroscience, Inc. P.A.T. and C.H.H. work as a consultants for Boston Scientific Neuromodulation and is inventor on a number of patents for invasive and noninvasive neuromodulation. C.B. is employed by Equip Health and receives salary and stock options.

Additional information


Extended data Extended data are available for this paper at <https://doi.org/10.1038/s41591-022-01941-w>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41591-022-01941-w>.

Correspondence and requests for materials should be addressed to Casey H. Halpern.

Peer review information *Nature Medicine* thanks Andreas Horn, Robert Reinhart and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Jerome Staal, in collaboration with the *Nature Medicine* team.

Reprints and permissions information is available at www.nature.com/reprints.



Extended Data Fig. 1 | 6-Month rDBS outcomes. Bilateral stimulation has been well tolerated by both subjects ($-1.5\mu\text{C}/\text{cm}^2$ charge density, 10 s duration). Both subjects report an increased sense of control specific to food cravings and eating-related behaviors. Here, behavior outcomes are reported at 6-months with stimulation (rDBS) compared to pre-surgery baseline. **A**) For both subjects, LOC frequency decreased with stimulation (*Subject 1: 16-point decrease; Subject 2: 13-point decrease*). **B**) With LOC episode severity, both subjects showed decrease in severity from baseline to 6-months with stimulation (*Subject 1: Baseline = 1.84 ± 0.69 ($n = 13$ samples), 6-month = 0.69 ± 0.053 ($n = 13$ samples), student's t -test, $p = 0.05$; Subject 2: Baseline = 0.84 ± 0.15 ($n = 13$ samples), 6-month = 0.15 ± 0.09 ($n = 13$ samples), student's t -test, $p = 0.09$). Further, both subjects also experienced decreases in **C**) For both subjects, Objective Binge Eating events (OBE) decreased with stimulation (*Subject 1: 8-point decrease; Subject 2: 12-point decrease*). **D**) Weight (kg, %) and **E**) BMI (*Subject 1: Weight = -5.9 kg, 4.5%, BMI = -2.2 ; Subject 2: Weight = -8.2 kg, 5.8%, BMI = -2.9). Bar graphs with error bars are presented as mean band power \pm S.E.**

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection Electrophysiologic data was obtained from intracranially placed depth leads by using commercially available Neuropace RNS system

Data analysis All data analyses were performed in (R2014b, The Mathworks Inc., MA) using custom scripts built upon the FieldTrip Toolbox (11; Donders Institute for Brain, Cognition and Behaviour, Radboud University, the Netherlands. See <http://fieldtriptoolbox.org>). No new algorithm or pre-processing techniques were performed outside of standard toolbox usage. The code for analyzing the data of this study are available from the corresponding author on reasonable request. The electrode artifacts from the co-registered post-operative CT, together with the pre-operative MRI, and atlas-based regions of interest were then loaded in DSI Studio for 3D rendering (<https://dsi-studio.labsolver.org/>). The pre-operative MRI anatomical images were co-registered to post-surgical CT scan using Advanced Normalization Tools (ANTs [20]) for electrode localization [21]

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data that support the findings of this study are available upon reasonable request to the corresponding author [CH]. The data are not publicly available due to them containing information that could compromise research participant privacy/consent. As this is part of an ongoing clinical trial, enrolling additional subjects

(Trial Registration # NCT03868670), all data and code will be deposited into Data Archive Brain Initiative (<https://dabi.loni.usc.edu>) as part of the BRAIN Initiative at the completion of the study. During this time, any request will be reviewed in a timely manner by the corresponding author, corresponding author's institution, and ultimately shared within reason of a signed data transfer agreement. All code has been made publicly available, and can be found https://github.com/rajatss123/LOC_NM_Code.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

The sample was 2 patients, the first 2 of a N=6 clinical study. No sample size calculation was made. Two was sufficient in that it was the first two patients declared as a pilot sample in an N=6 clinical trial. As this is an early feasibility study assessing safety, per FDA guidelines subjects enrolled in the study are staggered and in cohort of 2 before the next cohort can be enrolled with FDA approval.

Data exclusions

No data was excluded from this manuscript.

Replication

Data was replicated between two patients, the samples from which were sufficiently powered.

Randomization

No randomization occurred during the recording phase. One subject (Subject 1), per the FDA-guided protocol, was randomized to a SHAM stimulation safety period. For the buffet task (see supplementary information for more details), we presented a standard caloric meal (lunch or breakfast) prior to presenting the LOC buffet. During the LOC buffet, when subject reported they were losing control, the buffet was stopped within 10 minutes per protocol. For ambulatory data, in addition to self-report LOC (magnet swiping, see supplementary info), subjects were asked to swipe magnets during standard meals as well as during period when they were relaxed, not eating. All ambulatory LFP recordings were captured in the same configuration.

Blinding

The purpose of this trial is to assess the safety and feasibility of this potential therapeutic approach. Thus, prior to the stimulation phase subjects 1) underwent acute monopolar testing in clinic to assess for stimulation side effects and therapeutic parameters, and 2) underwent a safety single-blinded ON/OFF period in which subjects were sent home for 1 week stim ON, then 1 week stim OFF, then 4 weeks ON, followed by 1 week OFF before entering the unblinded open label phase. This was crucial to assess for stimulation-induced side effects and was part of the protocol design approved by the FDA (Wu et al, 2020). As this is a first-in-human early feasibility trial, primarily designed to assess safety/feasibility, we did not incorporate a double-blinded protocol which is typically used to assess efficacy.

Further, for this 2-subject cohort, per the FDA-guided protocol, Subject 1 additionally was randomized to a SHAM period in which the above Safety period was assessed but with stimulation OFF the entire period. During this time everyone involved in the study, except the programming clinician, was blinded. This period occurred right before participants entered the open-label phase of the study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- | | |
|-------------------------------------|---|
| n/a | Involved in the study |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Antibodies |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Human research participants |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Clinical data |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern |

Methods

- | | |
|-------------------------------------|---|
| n/a | Involved in the study |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

The first participant (Subject 1), a 45 year-old Caucasian woman with a body mass index (BMI) of 46 kg/m², underwent Roux-en-Y gastric bypass (RYGB) in 2005 and experienced an initial weight loss of 115 lbs. However, the participant gradually

regained the weight. At the time of enrollment, she was back to her pre-RYGB weight and met DSM-5 criteria for binge eating disorder, reporting at least 5 LOC eating bouts per week. At the time of enrollment, she had co-morbidities of Neoplasm, lower back pain, kyphoscoliosis/scoliosis, hypertension, esophageal reflux, dyslipidemia, complicated migraine, and anxiety. The second participant (Subject 2), a 56 year-old Caucasian woman with a BMI of 47 kg/m², underwent RYGB in 2005 and initially lost 152 lbs. Subject 2 maintained this weight loss for 6 years; however, she regained the weight in 2009 while both caring for an ill family member and recovering from a car accident. At the time of study enrollment, she was within 9% of her pre-RYGB weight and she reported LOC eating at least 4 times a week and met criteria for binge eating disorder as well. At the time of enrollment, she had a migraine co-morbidity. Both subjects reported severe cravings related to emotional and/or stress-related triggers that led to LOC eating. In addition to the RYGB, both subjects tried numerous other weight loss strategies including exercise, dieting, support groups, and medication as was required by our enrollment criteria.

Recruitment

Subjects were recruited through Stanford Bariatric Clinic, Newspaper (print and online), Facebook, or ResearchMatch. Participant bias is present as they are the ones self-reporting LOC severity (e.g. craving, hunger level). Over time, subjects became more aware of what was an LOC event and what was not. Participant bias as it relates to recruitment was present in that only those subjects deeming themselves at a symptom severity level worthy of this type of invasive intervention were responding to the ads for this study.

Ethics oversight

This study was approved by Stanford's Institutional Review Board (IRB-46563), and informed consent was obtained on all subjects. Neither participant was compensated for their participation.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration

Trial Registration # NCT03868670

Study protocol

Implantation of rDBS was performed for Subject 1 on January 31 2020, and for Subject 2 on July 17 2020. Timeline of procedures for both these subjects can be matched to these dates and expected timeline. The full study protocol can be accessed as part of this manuscript, and can be found here: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599841/>

Data collection

Data reported was collected on site on the fourth floor of Stanford University's Psychiatry Building at 401 Quarry Road, Palo Alto, CA. Data reported from ambulatory assessments was collected in the given patients naturalistic environment, collected in real-world settings.

Outcomes

Primary outcomes were LOC frequency and severity. These will both be acquired using the Ecological Momentary Assessment Questionnaires. Participants are asked to rate LOC immediately before and after any eating episode. Ratings for pre-meal LOC are made on a 5-point Likert-type scale. A rating of 1 on the scale corresponds to "complete control" and 5 signifies "complete LOC"; post-meal, participants respond to a "yes/no" question as to whether they had experienced LOC while eating. In addition, participants will be signaled at semi-random intervals several times a day to ask retrospectively about any episodes of LOC that may have taken place since the last signal. If the participant did not already fill out ratings about that episode, they are asked to do so at that time. In addition, participants are asked to fill out an end-of-the-day record to ensure that any and all LOC episodes are recorded. Assessment of LOC severity will involve several types of recordings to maximize the ability to capture episodes of LOC. These will include signal, interval contingent, and behavior contingent recordings. Signal contingent recording includes having the participant record their experiences whenever signaled at semi-random times by the researcher. In this study, participants will be signaled 5 semi-random times per day. Each response will require 2-3 minutes to complete. Compliance will be assessed by how often patients respond to signaled recordings (minimum inclusion criteria of 80% compliance). Behavior contingent recordings refer to having participants complete recordings before and after they engage in behaviors rather than in response to a text. Interval contingent recording includes recording at regular intervals determined ahead of time by the researcher. In this study, participants will complete an end of day recording as well. During monthly follow-ups, they will be queried about the details of each eating episode as well. All data will be automatically time- and date-stamped on smartphones and saved in a secure online database, providing the opportunity to delineate temporal relationships with LFP recordings and concordance with other assessments. Additionally, monthly reports of LOC severity using the Grilo Eating Loss of Control Scale (ELOCS) were obtained. The ELOCS is a self-report questionnaire that examines LOC-related behaviors on continuous Likert-type scales and the number of LOC episodes in the past 28 days. Given that LOC is a central diagnostic and clinical feature of multiple eating disorders, this comprehensive, validated, self-report measure of LOC was created to capture the varied experience of LOC among individuals by measuring different aspects of this construct as well as severity on continuous Likert-type scales. This scale does not diagnose the presence of LOC – this is done dichotomously (yes/no) and during a structured clinical interview for an eating disorder assessment, facilitated by the EDE-Q and ELOCS described above.

Secondary outcomes were weight, BMI, and reported personality measures, obtained monthly. Personality is measured using the Ecological Momentary Assessment Questionnaires. Participants are asked to rate mood, stress, hunger, and LOC immediately before and after any eating episode. Negative mood is assessed using an abbreviated Positive and Negative Affect Scale (PANAS) as LOC eating is typically preceded by negative emotion. This scale comprises the sum of 5 items (afraid, scared, upset, distressed, and jittery), all of which are rated on a 5-point scale. Weight and BMI were obtained monthly, assessed and reported to the clinical team by the subject themselves.